The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration

Nathan T Ihle; Robert T Abraham

doi:10.1016/j.molcel.2017.02.030

The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration

Mol Cell. 2017 Mar 16;65(6):959-960. doi: 10.1016/j.molcel.2017.02.030.

Authors

Nathan T Ihle¹, Robert T Abraham²

Affiliations

¹ Oncology R&D Group, Pfizer Worldwide Research & Development, 10646/CB4, Science Center Drive, San Diego, CA 92121, USA.
² Oncology R&D Group, Pfizer Worldwide Research & Development, 10646/CB4, Science Center Drive, San Diego, CA 92121, USA. Electronic address: robert.abraham@pfizer.com.

PMID: 28306509
DOI: 10.1016/j.molcel.2017.02.030

Abstract

The PARK2 gene encodes an ubiquitin E3 ligase that is involved in mitochondrial homeostasis and linked to Parkinson's disease. In this issue, Gupta et al. (2017) demonstrate that PARK2 expression is frequently reduced in human cancers and that this alteration leads to dysregulated PI3K signaling.

MeSH terms

Humans
Mitochondria
Neoplasms
Parkinson Disease / genetics
Phosphatidylinositol 3-Kinases*
Ubiquitin
Ubiquitin-Protein Ligases / genetics*

Substances

Ubiquitin
Ubiquitin-Protein Ligases
Phosphatidylinositol 3-Kinases